OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease
Qiang Ren, Ya Chen, Zongtao Zhou, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 9, pp. 6082-6104
Closed Access | Times Cited: 13
Qiang Ren, Ya Chen, Zongtao Zhou, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 9, pp. 6082-6104
Closed Access | Times Cited: 13
Showing 13 citing articles:
Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets
Joshua S. Fleishman, Sunil Kumar
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 77
Joshua S. Fleishman, Sunil Kumar
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 77
Discovery of First-in-Class FXR and HSD17B13 Dual Modulator for the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease
Shixuan Jiao, Qiang Ren, Lianru Chen, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 2
Shixuan Jiao, Qiang Ren, Lianru Chen, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 2
Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease
Wanqiu Huang, Zhijun Cao, Wenxin Wang, et al.
Bioorganic Chemistry (2024) Vol. 143, pp. 107071-107071
Closed Access | Times Cited: 6
Wanqiu Huang, Zhijun Cao, Wenxin Wang, et al.
Bioorganic Chemistry (2024) Vol. 143, pp. 107071-107071
Closed Access | Times Cited: 6
Upregulation of Hepatic Glutathione S-Transferase Alpha 1 Ameliorates Metabolic Dysfunction-Associated Steatosis by Degrading Fatty Acid Binding Protein 1
Jing Jiang, Hu Li, Mei Tang, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5086-5086
Open Access | Times Cited: 4
Jing Jiang, Hu Li, Mei Tang, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5086-5086
Open Access | Times Cited: 4
Recent advances in small molecule design strategies against hepatic fibrosis
Heming Chen, Wei Su, Tingting Li, et al.
European Journal of Medicinal Chemistry (2025) Vol. 286, pp. 117281-117281
Closed Access
Heming Chen, Wei Su, Tingting Li, et al.
European Journal of Medicinal Chemistry (2025) Vol. 286, pp. 117281-117281
Closed Access
Discovery of the First-in-class FABP/PPAR Multiple Modulator for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Ya Chen, Zibin Liao, Jianming Mao, et al.
European Journal of Medicinal Chemistry (2025), pp. 117635-117635
Closed Access
Ya Chen, Zibin Liao, Jianming Mao, et al.
European Journal of Medicinal Chemistry (2025), pp. 117635-117635
Closed Access
The Chinese Herbal TiaoGanXiaoZhi Formula Alleviates the Progression of Metabolic‐Associated Fatty Liver Disease by Regulating the Gut Microbiota
Wenying Qi, Xu Cao, Yue Chen, et al.
Portal hypertension & cirrhosis (2025)
Open Access
Wenying Qi, Xu Cao, Yue Chen, et al.
Portal hypertension & cirrhosis (2025)
Open Access
Dual Modulator of FXR and HSD17B13: Revitalizing FXR Therapies in MASH
Changhong Wei, Yun Liu, Zhiming Yan, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Changhong Wei, Yun Liu, Zhiming Yan, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders
Stefano Fiorucci, Valentina Sepe, Michele Biagioli, et al.
Biochemical Pharmacology (2023) Vol. 216, pp. 115776-115776
Closed Access | Times Cited: 9
Stefano Fiorucci, Valentina Sepe, Michele Biagioli, et al.
Biochemical Pharmacology (2023) Vol. 216, pp. 115776-115776
Closed Access | Times Cited: 9
Patented Farnesoid X receptor modulators: a review (2019 – present)
Antimo Gioiello, Emiliano Rosatelli, Bruno Cerra
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 7, pp. 547-564
Closed Access | Times Cited: 3
Antimo Gioiello, Emiliano Rosatelli, Bruno Cerra
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 7, pp. 547-564
Closed Access | Times Cited: 3
Dual-function natural products: Farnesoid X receptor agonist/inflammation inhibitor for metabolic dysfunction-associated steatotic liver disease therapy
Kang Wang, Pengfei Zhang, Huiyong Sun, et al.
Chinese Journal of Natural Medicines (2024) Vol. 22, Iss. 11, pp. 965-976
Closed Access | Times Cited: 2
Kang Wang, Pengfei Zhang, Huiyong Sun, et al.
Chinese Journal of Natural Medicines (2024) Vol. 22, Iss. 11, pp. 965-976
Closed Access | Times Cited: 2
Tailoring FXR Modulators for Intestinal Specificity: Recent Progress and Insights
Amanda Maria Morrison, Bahaa Elgendy
Molecules (2024) Vol. 29, Iss. 9, pp. 2022-2022
Open Access | Times Cited: 1
Amanda Maria Morrison, Bahaa Elgendy
Molecules (2024) Vol. 29, Iss. 9, pp. 2022-2022
Open Access | Times Cited: 1
Design, synthesis, and biological evaluation of novel highly selective non-carboxylic acid FABP1 inhibitors
Lianru Chen, Bin Wang, Hongming Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116705-116705
Closed Access
Lianru Chen, Bin Wang, Hongming Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116705-116705
Closed Access
